State Board of Administration of Florida Retirement System increased its stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 6.9% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 54,139 shares of the biopharmaceutical company’s stock after acquiring an additional 3,510 shares during the quarter. State Board of Administration of Florida Retirement System owned approximately 0.11% of Agios Pharmaceuticals worth $3,614,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of AGIO. QS Investors LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $144,000. Cubist Systematic Strategies LLC grew its holdings in shares of Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 3,123 shares during the last quarter. Aperio Group LLC acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $206,000. Parametrica Management Ltd acquired a new position in shares of Agios Pharmaceuticals in the 2nd quarter worth $228,000. Finally, Janney Montgomery Scott LLC grew its holdings in shares of Agios Pharmaceuticals by 9.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 425 shares during the last quarter. Institutional investors and hedge funds own 93.16% of the company’s stock.
A number of equities analysts recently issued reports on AGIO shares. ValuEngine upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Royal Bank Of Canada started coverage on Agios Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $78.00 target price on the stock. J P Morgan Chase & Co restated a “buy” rating and issued a $76.00 target price on shares of Agios Pharmaceuticals in a report on Monday, September 18th. SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. Finally, Credit Suisse Group lifted their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $75.70.
In related news, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $63.85, for a total transaction of $383,100.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David P. Schenkein sold 80,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $70.14, for a total value of $5,611,200.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 178,908 shares of company stock valued at $12,147,719. Insiders own 10.55% of the company’s stock.
Shares of Agios Pharmaceuticals, Inc. (NASDAQ AGIO) opened at $59.46 on Wednesday. Agios Pharmaceuticals, Inc. has a 12-month low of $39.24 and a 12-month high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The business had revenue of $11.35 million during the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s revenue was up 26.4% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.63) earnings per share. equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.59 EPS for the current fiscal year.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).
Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.